Skip to main content

Table 3 Cellular expression levels (+ %) of immunological biomarkers in early- ART suppressed HIV-infected subjects a

From: Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease

  n = 24 ART time point 1 ART time point 2 P valuea
Gender   58.30% /
Age Years 46 (42–48.7) 48 (44–50) /
Length of time on ART Months 6.4 (4.8–13.9) 29.3 (27.3–38.9) /
Viral Load copies/mL 75 (56.2–75) 75 (56.2 - 75) ns
CD4+ T cells Total (cells/uL) 300.0 (222.5–360.7) 425 (328.25–513.5) <0.0001
CD8+ T cells Total (cells/uL) 1085 (710–1396) 1114 (750.3–1593) ns
SSC++Lin- (+%) CD11c+ mDCs (HLADR+CD11c+) 3.9 (2.7–5.4) 2.8 (2.3–4.4) ns
  Classical Monocytes (HLADR+CD11c+CD14hiCD16-) 70.3 (67.8–75.1) 78.8 (74.35–83.1) 0.004
  Non-Classical Monocytes (HLADR+CD11c+CD14dimCD16+) 3.0 (1.6–6.2) 3.8 (2.3–5.7) ns
Classical Monocytes (HLADR+CD11c+CD14hiCD16-) HLA-DR gMFI 14375(10569–16546) 12516 (10343–15220) ns
  CD11b gMFI 31139 (26954–34508) 31096 (27432–34876) ns
  CD11c gMFI 13514 (10406–14970) 12069 (10430–13956) 0.008
  CD33 gMFI 29624 (20462–36580) 29938 (19164–37687) ns
Non-Classical Monocytes (HLADR+CD11c+CD14dimCD16+) HLA-DR gMFI 12311 (10047–14272) 12993 (11328–14673) ns
  CD11b gMFI 2123 (1726–3767) 2421 (1756–2957) ns
  CD11c gMFI 21517 (17876–24957) 22780 (20620–24761) ns
  CD33 gMFI 8678 (6510–11084) 8956 (6472–11433) ns
CD14+ monocytes HO-1 gMFI 16290 (14784–18027) 15785 (13875–18535) ns
  1. aEarly HAART-suppressed subjects had VL <100 copies/mL after initial viral suppression, with only one blip of >1000 copies/mL permissible during the time frame of analysis on HAART. Early HAART time point refers to a period between 2–10 months of treatment initiation, at a time when VL had achieved an undetectable level.